论文部分内容阅读
为了探讨cerbB2、p53、CEA及PCNA在非小细胞肺癌中的表达及其与临床的关系,采用免疫组化LSAB方法,对23例非小细胞肺癌进行检测,结果显示,在腺癌的p53,CEA,cerbB2表达阳性率分别为44%,66%,77%,鳞癌的表达阳性率分别为21%,28%,35%;鳞癌的阳性表达率明显低于腺癌。cerbB2、p53、CEA阳性表达与淋巴结转移无关(P>0.05),只有PCNA阳性表达与淋巴结转移有关,在有淋巴结转移和无淋巴结转移的非小细胞肺癌的患者中,PCNA表达的阳性率分别为25%和9%,淋巴结转移患者的PCNA表达阳性率明显高于无淋巴结转移者(P<0.05)。p53、CEA的表达与生存期有关,生存6个月以下和12个月的患者的p53表达阳性率分别为50%,20%(P<0.05),CEA的阳性率分别为60%,40%(P<0.05),从而提示p53和CEA表达阳性率越高,患者生存期越短,预后差。
To investigate the expression of cerbB2, p53, CEA, and PCNA in non-small cell lung cancer and its relationship with the clinic, 23 cases of non-small cell lung cancer were detected by immunohistochemical LSAB method. The positive rates of p53, CEA and cerbB2 expression were 44%, 66%, and 77%, respectively. The positive rates of squamous cell carcinoma were 21%, 28%, and 35%, respectively; the positive rate of squamous cell carcinoma was significantly lower. In adenocarcinoma. The positive expression of c-erbB-2, p53 and CEA was not related to lymph node metastasis (P>0.05). Only PCNA positive expression was associated with lymph node metastasis. PCNA was found in patients with non-small cell lung cancer with lymph node metastasis and no lymph node metastasis. The positive rates of expression were 25% and 9% respectively, and the positive rate of PCNA expression in patients with lymph node metastasis was significantly higher than those without lymph node metastasis (P<0.05). The expression of p53 and CEA was related to the survival period. The positive rate of p53 expression in patients who survived 6 months and 12 months was 50% and 20% respectively (P<0.05). The positive rate of CEA was 60%, respectively. 40% (P<0.05), suggesting that the higher the positive rate of p53 and CEA expression, the shorter the survival time and the poor prognosis.